Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) …
Type and hit ENTER
Announcements
June 3, 2019
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European …
September 18, 2018
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for …
June 4, 2018
ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative …
June 1, 2018
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s …
October 27, 2017
ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society …
June 19, 2017
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of …
May 17, 2017
ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for …
May 10, 2017
ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior Project Manager, and will …
May 9, 2016
ProAxsis CEO David Ribeiro was interviewed by ProActive Investors UK. Watch the video on Stock-Tube
May 4, 2016
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
Copyright © 2016-2018 - ProAxsis - All rights reserved.
Announcements Archives | ProAxsis